Abstract:Membranous nephropathy (MN) is a common glomerular disease in adults characterized by the deposition of immune complexes on the glomerular basement membrane, leading to proteinuria and renal function decline. In recent years, there has been a significant shift in the therapeutic strategies for MN, particularly with the development and application of targeted therapeutic drugs. These targeted therapies primarily focus on specific molecules and pathways, offering a more precise treatment option that directly targets the pathological mechanisms of the disease. This approach reduces the side effects associated with traditional immunosuppressive treatments and enhances therapeutic efficacy. This review included the latest literature both domestically and internationally, integrating information on target antigens and corresponding targeted therapeutic drugs, with the goal of providing a theoretical basis for clinical treatment.